Lakefront Biotherapeutics Stock Rises 4% After Share Repurchase Update

Lakefront Biotherapeutics (LKFT) plans to start registrational trials for gamgertamig in 2027, following a restructuring and acquisition of assets from Ouro Medicines. Gilead Sciences (GILD) and Lakefront completed the acquisition of Ouro Medicines to expand their inflammation pipeline. Nektar Therapeutics (NKTR) is advancing its immunology and oncology pipeline through research collaborations.

Lakefront Biotherapeutics (LKFT) announced that the U.S. FDA granted Orphan Drug Designation to gamgertamig for treating pemphigus, adding to prior designations for AIHA and ITP. The drug is in Phase 1b trials for autoimmune diseases, with expansion planned in 2027. Lakefront is developing gamgertamig with Gilead Sciences, aiming for registrational studies next year.

Lakefront Biotherapeutics NV (LKFT) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update Completed acquisition of Ouro Medicines with Gilead Sciences to advance potential first and best-in-class T-cell engager Forecast at least €1.6B of cash remaining after fu

Lakefront Biotherapeutics (LKFT) reported half-year 2026 results and updated its business after completing its Ouro Medicines acquisition with Gilead in June. It forecast at least €1.6B dry powder after funding gamgertamig to first approval, and maintained ~€2B year-end cash and investments guidance, now including a €50M share repurchase. H1 2026 net revenues were €18.6M and net profit was €16.6M.

Lakefront Biotherapeutics (Euronext & NASDAQ: LKFT) said it has launched a €50 million share repurchase program, allowing open-market purchases of ordinary shares through Dec. 31, 2026. The company will hold repurchased shares as treasury shares. The program was set up with Morgan Stanley & Co International PLC, and updates will be provided as required.

Tencent (700) plans to raise up to $5bn via offshore bonds for AI and data centers. It repurchased 1.191M shares (HK$501.9M) in early October. The company also reinvested in Manus alongside other investors.